Altered gene expression in busulfan-resistant human myeloid leukemia
about
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxiaPredictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.IKK{gamma} protein is a target of BAG3 regulatory activity in human tumor growth.BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes.The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodelingEffects of the proapoptotic regulator Bcl-2/adenovirus EIB 19-kDa-interacting protein 3 on the chemosensitivity of human colon cancer cell lines.The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.BAK activation is necessary and sufficient to drive ceramide synthase-dependent ceramide accumulation following inhibition of BCL2-like proteins.Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cellsBAG3: a multifaceted protein that regulates major cell pathways.New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy.Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.BIK (NBK) is a mediator of the sensitivity of Fanconi anaemia group C lymphoblastoid cell lines to interstrand DNA cross-linking agents.BAG3 controls angiogenesis through regulation of ERK phosphorylation.MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL familyOverexpressed BAG3 is a potential therapeutic target in chronic lymphocytic leukemia.Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions.
P2860
Q33470265-43008A2F-FF8F-478C-9E8F-53D3D4303BF7Q33561227-E2B6C52C-51C1-42F0-B68F-657B7B2FF592Q33636086-F9F481A1-F162-403F-9525-85C8D2F71086Q33665187-BD2F7F14-1F58-42F4-AE1E-A00AE83147C3Q33842059-05F66679-CCDE-4824-A0FC-A587C7D72C56Q34085382-ABC0EE8E-12DE-48F2-AA68-513EEBA3B506Q34425136-26954DD8-5423-432E-93DC-89DF035F0588Q34498134-A55CA1BD-01A1-4ED4-9C63-FB16CA4E9C04Q35060679-E6F7AE57-8E88-4F4F-891E-8AFFC66F6880Q35136616-62DF17D0-D2EE-4C4F-83C1-2962C4C96F01Q35691048-46E3F5A0-4A17-477D-B04F-8DE358159270Q36208342-87D791C1-FD96-4577-A858-089F925F86C8Q36247606-5517BC98-4AF6-4CDE-B365-C3C321590724Q36813008-B9AAE47F-24B0-490A-A5F9-DDFD1F29C40AQ37140698-E5C16CCE-69D9-444F-B886-DAB3E7E72A65Q37213049-0C5962DF-B597-49EB-9473-3A8204A256A3Q37862582-8F7AB181-F7BD-4A50-BBBE-BB15671472F5Q38036571-646A5D92-459A-4E26-B92E-38A7BA2B4DE0Q38398064-F9F0BF12-C33F-4FC6-AF00-F99E2A4E3A09Q39300776-DD402A3E-B007-43CC-8F94-B348BF849FA4Q39400810-AA299FA0-0F77-417B-ABA7-05C9526D1581Q41839159-878F73A9-0F0A-41F6-BF00-6636ADF8F2E5Q47695857-AB0231FD-0636-4FE2-A8B7-AC0C20E3B4ACQ49989774-18347640-AE74-4645-99A1-2B52FAC0DAEBQ51016254-5B10F639-4722-407C-A85F-69A93C3A172C
P2860
Altered gene expression in busulfan-resistant human myeloid leukemia
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Altered gene expression in busulfan-resistant human myeloid leukemia
@en
type
label
Altered gene expression in busulfan-resistant human myeloid leukemia
@en
prefLabel
Altered gene expression in busulfan-resistant human myeloid leukemia
@en
P2093
P2860
P1433
P1476
Altered gene expression in busulfan-resistant human myeloid leukemia
@en
P2093
Benigno C Valdez
Borje S Andersson
Daniel Betancourt
David Murray
Latha Ramdas
Marcos de Lima
Richard E Champlin
Steven Kornblau
P2860
P304
P356
10.1016/J.LEUKRES.2008.01.016
P577
2008-03-12T00:00:00Z